Tejara Capital Ltd Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Tejara Capital Ltd purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 4th quarter, Holdings Channel.com reports. The fund purchased 28,781 shares of the specialty pharmaceutical company’s stock, valued at approximately $825,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COLL. Victory Capital Management Inc. raised its position in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after acquiring an additional 215,874 shares in the last quarter. JPMorgan Chase & Co. raised its position in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after acquiring an additional 175,892 shares in the last quarter. Empowered Funds LLC bought a new stake in Collegium Pharmaceutical during the third quarter worth $4,693,000. Massachusetts Financial Services Co. MA raised its position in Collegium Pharmaceutical by 17.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after acquiring an additional 116,327 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $2,432,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on COLL. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. Finally, Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Price Performance

NASDAQ:COLL opened at $29.67 on Tuesday. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The firm has a market cap of $934.19 million, a price-to-earnings ratio of 12.79 and a beta of 0.99. The firm’s 50-day simple moving average is $30.88 and its 200 day simple moving average is $32.87. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. As a group, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now directly owns 165,246 shares in the company, valued at $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,961 shares of company stock valued at $3,146,634. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.